Kyntheum

Brodalumab, the active ingredient in Kyntheum, is an IL‑17 receptor A antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients, helping to reduce skin lesions and improve quality of life.

GNH USA supplies Kyntheum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable cold‑chain logistics for biologic medicines. The product complies with EU regulatory standards and is available for global distribution.

Brodalumab targets the IL‑17 mediated pathway in psoriasis.

Moderate to severe plaque psoriasis: reduces skin lesions and improves patient quality of life.

Brodalumab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory infections: mild cold‑like symptoms. - Headache: occasional mild to moderate headache. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Suicidal ideation: new or worsening thoughts of self‑harm. - Severe infections: signs of bacterial or fungal infection requiring medical attention. - Allergic reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, several safety considerations should be observed. - Pregnancy: safety not established; avoid use unless benefits outweigh risks. - Screening: assess for active infections before initiating therapy. - Monitoring: observe for signs of depression or suicidal thoughts during treatment. - Immunosuppression: avoid live vaccines while receiving brodalumab. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Brodalumab can interact with other agents that affect immune function.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection. - Immunosuppressive biologics: combined use may increase infection risk.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may mask infection signs. - Cyclosporine: additive immunosuppression potential. - Antifungal agents: monitor for increased infection risk.